{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:51:50Z","timestamp":1774626710653,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,27]]},"DOI":"10.7759\/cureus.105973","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:39:12Z","timestamp":1774622352000},"source":"Crossref","is-referenced-by-count":0,"title":["Clostridioides difficile Infection in Hematology-Oncology Patients Receiving Bacterial Prophylaxis With Levofloxacin: A Single-Institution Experience"],"prefix":"10.7759","author":[{"given":"Aleksandra M","family":"Sobiborowicz-Sadowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Chebat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis J","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac074","article-title":"Chemotherapy-induced neutropenia and febrile neutropenia in the US: a beast of burden that needs to be tamed?","volume":"27","author":"Boccia R","year":"2022","unstructured":"Boccia R, Glaspy J, Crawford J, Aapro M. Chemotherapy-induced neutropenia and febrile neutropenia in the US: a beast of burden that needs to be tamed?. Oncologist. 2022, 27:625-36. 10.1093\/oncolo\/oyac074","journal-title":"Oncologist"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044097","article-title":"Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia","volume":"353","author":"Bucaneve G","year":"2005","unstructured":"Bucaneve G, Micozzi A, Menichetti F, et al.. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005, 353:977-87. 10.1056\/NEJMoa044097","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.12512","article-title":"Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation: a randomized clinical trial","volume":"320","author":"Alexander S","year":"2018","unstructured":"Alexander S, Fisher BT, Gaur AH, et al.. Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation: a randomized clinical trial. JAMA. 2018, 320:995-1004. 10.1001\/jama.2018.12512","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.11.017","article-title":"Safety and efficacy of prophylactic levofloxacin in pediatric and adult hematopoietic stem cell transplantation patients","volume":"28","author":"Gardner JC","year":"2022","unstructured":"Gardner JC, Courter JD, Dandoy CE, Davies SM, Teusink-Cross A. Safety and efficacy of prophylactic levofloxacin in pediatric and adult hematopoietic stem cell transplantation patients. Transplant Cell Ther. 2022, 28:167.e1-5. 10.1016\/j.jtct.2021.11.017","journal-title":"Transplant Cell Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz RA","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ, et al.. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018, 36:3043-54. 10.1200\/JCO.18.00374","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.39029","article-title":"Antibiotics associated with Clostridium difficile infection","volume":"15","author":"Rafey A","year":"2023","unstructured":"Rafey A, Jahan S, Farooq U, Akhtar F, Irshad M, Nizamuddin S, Parveen A. Antibiotics associated with Clostridium difficile infection. Cureus. 2023, 15:e39029. 10.7759\/cureus.39029","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/piaa090","article-title":"Clostridioides difficile infections in inpatient pediatric oncology patients: a cohort study evaluating risk factors and associated outcomes","volume":"10","author":"Willis DN","year":"2021","unstructured":"Willis DN, Huang FS, Elward AM, Wu N, Magnusen B, Dubberke ER, Hayashi RJ. Clostridioides difficile infections in inpatient pediatric oncology patients: a cohort study evaluating risk factors and associated outcomes. J Pediatric Infect Dis Soc. 2021, 10:302-8. 10.1093\/jpids\/piaa090","journal-title":"J Pediatric Infect Dis Soc"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102604","article-title":"Guideline for the management of Clostridioides difficile infection in pediatric patients with cancer and hematopoietic cell transplantation recipients: 2024 update","volume":"72","author":"Patel P","year":"2024","unstructured":"Patel P, Robinson PD, Fisher BT, et al.. Guideline for the management of Clostridioides difficile infection in pediatric patients with cancer and hematopoietic cell transplantation recipients: 2024 update. EClinicalMedicine. 2024, 72:102604. 10.1016\/j.eclinm.2024.102604","journal-title":"EClinicalMedicine"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001278","article-title":"ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections","volume":"116","author":"Kelly CR","year":"2021","unstructured":"Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stollman NH. ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. Am J Gastroenterol. 2021, 116:1124-47. 10.14309\/ajg.0000000000001278","journal-title":"Am J Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy822","article-title":"Oral vancomycin prophylaxis is highly effective in preventing Clostridium difficile infection in allogeneic hematopoietic cell transplant recipients","volume":"68","author":"Ganetsky A","year":"2019","unstructured":"Ganetsky A, Han JH, Hughes ME, et al.. Oral vancomycin prophylaxis is highly effective in preventing Clostridium difficile infection in allogeneic hematopoietic cell transplant recipients. Clin Infect Dis. 2019, 68:2003-9. 10.1093\/cid\/ciy822","journal-title":"Clin Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir301","article-title":"Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection","volume":"53","author":"Stevens V","year":"2011","unstructured":"Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis. 2011, 53:42-8. 10.1093\/cid\/cir301","journal-title":"Clin Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2022.08.030","article-title":"Clostridioides difficile infection in hospitalized pediatric patients: comparisons of epidemiology, testing, and treatment from 2013 to 2019","volume":"252","author":"Edwards PT","year":"2023","unstructured":"Edwards PT, Thurm CW, Hall M, et al.. Clostridioides difficile infection in hospitalized pediatric patients: comparisons of epidemiology, testing, and treatment from 2013 to 2019. J Pediatr. 2023, 252:111-116.e1. 10.1016\/j.jpeds.2022.08.030","journal-title":"J Pediatr"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/08880018.2019.1711473","article-title":"Clostridium difficile infection in a children's hospital with specific patterns among pediatric oncology and hematopoietic stem cell transplantation populations","volume":"37","author":"Spruit JL","year":"2020","unstructured":"Spruit JL, Knight T, Sweeney C, Salimnia H, Sava\u015fan S. Clostridium difficile infection in a children's hospital with specific patterns among pediatric oncology and hematopoietic stem cell transplantation populations. Pediatr Hematol Oncol. 2020, 37:211-22. 10.1080\/08880018.2019.1711473","journal-title":"Pediatr Hematol Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023-062307","article-title":"Clostridioides difficile infection in children: recent updates on epidemiology, diagnosis, therapy","volume":"152","author":"Shirley DA","year":"2023","unstructured":"Shirley DA, Tornel W, Warren CA, Moonah S. Clostridioides difficile infection in children: recent updates on epidemiology, diagnosis, therapy. Pediatrics. 2023, 152:4-6. 10.1542\/peds.2023-062307","journal-title":"Pediatrics"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/srep31498","article-title":"Risk factors for Clostridium difficile infection in hemato-oncological patients: a case control study in 144 patients","volume":"6","author":"Fuereder T","year":"2016","unstructured":"Fuereder T, Koni D, Gleiss A, Kundi M, Makristathis A, Zielinski C, Steininger C. Risk factors for Clostridium difficile infection in hemato-oncological patients: a case control study in 144 patients. Sci Rep. 2016, 6:31498. 10.1038\/srep31498","journal-title":"Sci Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e08450","article-title":"To study the contributing factors and outcomes of Clostridioides difficile infection in patients with solid tumors","volume":"7","author":"Sahu KK","year":"2021","unstructured":"Sahu KK, Mishra AK, Jindal V, Siddiqui AD, George SV. To study the contributing factors and outcomes of Clostridioides difficile infection in patients with solid tumors. Heliyon. 2021, 7:e08450. 10.1016\/j.heliyon.2021.e08450","journal-title":"Heliyon"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.3846","article-title":"CDC's hospital-onset Clostridioides difficile prevention framework in a regional hospital network","volume":"7","author":"Turner NA","year":"2024","unstructured":"Turner NA, Krishnan J, Nelson A, et al.. CDC's hospital-onset Clostridioides difficile prevention framework in a regional hospital network. JAMA Netw Open. 2024, 7:e243846. 10.1001\/jamanetworkopen.2024.3846","journal-title":"JAMA Netw Open"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.633","article-title":"Using oral vancomycin as prophylaxis against Clostridioides difficile infection in stem cell transplant recipients is associated with increased Gram negative bacteremia","volume":"30","author":"Vartanov AR","year":"2024","unstructured":"Vartanov AR, Shestovska Y, Hamby M, et al.. Using oral vancomycin as prophylaxis against Clostridioides difficile infection in stem cell transplant recipients is associated with increased Gram negative bacteremia. Transplant Cell Ther. 2024, 30:440. 10.1016\/j.jtct.2023.12.633","journal-title":"Transplant Cell Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-018-3316-5","article-title":"Incidence, course, and outcome of Clostridium difficile infection in children with hematological malignancies or undergoing hematopoietic stem cell transplantation","volume":"37","author":"Salamonowicz M","year":"2018","unstructured":"Salamonowicz M, Ociepa T, Fr\u0105czkiewicz J, et al.. Incidence, course, and outcome of Clostridium difficile infection in children with hematological malignancies or undergoing hematopoietic stem cell transplantation. Eur J Clin Microbiol Infect Dis. 2018, 37:1805-12. 10.1007\/s10096-018-3316-5","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1542\/hpeds.2023-007154","article-title":"Risk factors for recurrent Clostridioides difficile infection in children","volume":"13","author":"Lee P","year":"2023","unstructured":"Lee P, Nemati K, Silver EJ, Cacace J, Goldman DL. Risk factors for recurrent Clostridioides difficile infection in children. Hosp Pediatr. 2023, 13:1010-7. 10.1542\/hpeds.2023-007154","journal-title":"Hosp Pediatr"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-031807","article-title":"Oral vancomycin as secondary prophylaxis for Clostridioides difficile infection","volume":"148","author":"Bao H","year":"2021","unstructured":"Bao H, Lighter J, Dubrovskaya Y, Merchan C, Siegfried J, Papadopoulos J, Jen SP. Oral vancomycin as secondary prophylaxis for Clostridioides difficile infection. Pediatrics. 2021, 148:16-8. 10.1542\/peds.2020-031807","journal-title":"Pediatrics"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/434887-clostridioides-difficile-infection-in-hematology-oncology-patients-receiving-bacterial-prophylaxis-with-levofloxacin-a-single-institution-experience","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:39:12Z","timestamp":1774622352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/434887-clostridioides-difficile-infection-in-hematology-oncology-patients-receiving-bacterial-prophylaxis-with-levofloxacin-a-single-institution-experience"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.105973","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,27]]}}}